Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors

Toshiaki Kikuchi, Malcolm A.S. Moore, Ronald Crystal

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

CD40 ligand (CD40L) is essential for the initiation of antigen-specific T-cell responses. This study is based on the hypothesis that dendritic cells (DCs) genetically modified ex vivo to express CD40L will enhance in vivo presentation of tumor antigen to the cellular immune system with consequent induction of antitumor immunity to suppress tumor growth. To examine this concept, subcutaneous murine tumors were injected with bone marrow-derived DCs that had been modified in vitro with an adenovirus (Ad) vector expressing murine CD40L (AdmCD40L). In B16 (H-2 b, melanoma) and CT26 (H-2(d), colon cancer murine models, intratumoral injection of 2 x 10 6 Adm-CD40L-modified DCs (CD40L-DCs) to established (day 8) subcutaneous tumors resulted in sustained tumor regression and survival advantage. This antitumor effect was sustained when the number of CD40L-DCs were reduced 10-fold to 2 x 10 5. Analysis of spleens from CD40L-DC-treated animals demonstrated that CD40L-DCs injected into the subcutaneous CT26 flank tumors migrated to the spleen, resulting in activation of immune-relevant processes. Consistent with this concept, intratumoral administration of CD40L-DCs elicited tumor-specific cytotoxic T-lymphocyte responses, and the transfer of spleen cells from CD40L-DC-treated mice efficiently protected naive mice against a subsequent tumor challenge. In a distant 2-tumor model of metastatic disease, an untreated B16 tumor in the right flank regressed in parallel with a left B16 tumor treated with direct injection of CD40L-DCs. These results support the concept that genetic modification of DCs with a recombinant CD40L adenovirus vector may be a useful strategy for directly activating DCs for cancer immunotherapy. (C) 2000 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)91-99
Number of pages9
JournalBlood
Volume96
Issue number1
Publication statusPublished - 1 Jul 2000
Externally publishedYes

Fingerprint

CD40 Ligand
Dendritic Cells
Tumors
Immunity
Neoplasms
Therapeutics
T-cells
Spleen
Adenoviridae
Genetic Phenomena
Injections
Immune system
Direct injection
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Immunotherapy
Colonic Neoplasms
Immune System
Melanoma
Bone

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. / Kikuchi, Toshiaki; Moore, Malcolm A.S.; Crystal, Ronald.

In: Blood, Vol. 96, No. 1, 01.07.2000, p. 91-99.

Research output: Contribution to journalArticle

@article{df8f23aae41b456dbc2ff8ea76b03a41,
title = "Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors",
abstract = "CD40 ligand (CD40L) is essential for the initiation of antigen-specific T-cell responses. This study is based on the hypothesis that dendritic cells (DCs) genetically modified ex vivo to express CD40L will enhance in vivo presentation of tumor antigen to the cellular immune system with consequent induction of antitumor immunity to suppress tumor growth. To examine this concept, subcutaneous murine tumors were injected with bone marrow-derived DCs that had been modified in vitro with an adenovirus (Ad) vector expressing murine CD40L (AdmCD40L). In B16 (H-2 b, melanoma) and CT26 (H-2(d), colon cancer murine models, intratumoral injection of 2 x 10 6 Adm-CD40L-modified DCs (CD40L-DCs) to established (day 8) subcutaneous tumors resulted in sustained tumor regression and survival advantage. This antitumor effect was sustained when the number of CD40L-DCs were reduced 10-fold to 2 x 10 5. Analysis of spleens from CD40L-DC-treated animals demonstrated that CD40L-DCs injected into the subcutaneous CT26 flank tumors migrated to the spleen, resulting in activation of immune-relevant processes. Consistent with this concept, intratumoral administration of CD40L-DCs elicited tumor-specific cytotoxic T-lymphocyte responses, and the transfer of spleen cells from CD40L-DC-treated mice efficiently protected naive mice against a subsequent tumor challenge. In a distant 2-tumor model of metastatic disease, an untreated B16 tumor in the right flank regressed in parallel with a left B16 tumor treated with direct injection of CD40L-DCs. These results support the concept that genetic modification of DCs with a recombinant CD40L adenovirus vector may be a useful strategy for directly activating DCs for cancer immunotherapy. (C) 2000 by The American Society of Hematology.",
author = "Toshiaki Kikuchi and Moore, {Malcolm A.S.} and Ronald Crystal",
year = "2000",
month = "7",
day = "1",
language = "English",
volume = "96",
pages = "91--99",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors

AU - Kikuchi, Toshiaki

AU - Moore, Malcolm A.S.

AU - Crystal, Ronald

PY - 2000/7/1

Y1 - 2000/7/1

N2 - CD40 ligand (CD40L) is essential for the initiation of antigen-specific T-cell responses. This study is based on the hypothesis that dendritic cells (DCs) genetically modified ex vivo to express CD40L will enhance in vivo presentation of tumor antigen to the cellular immune system with consequent induction of antitumor immunity to suppress tumor growth. To examine this concept, subcutaneous murine tumors were injected with bone marrow-derived DCs that had been modified in vitro with an adenovirus (Ad) vector expressing murine CD40L (AdmCD40L). In B16 (H-2 b, melanoma) and CT26 (H-2(d), colon cancer murine models, intratumoral injection of 2 x 10 6 Adm-CD40L-modified DCs (CD40L-DCs) to established (day 8) subcutaneous tumors resulted in sustained tumor regression and survival advantage. This antitumor effect was sustained when the number of CD40L-DCs were reduced 10-fold to 2 x 10 5. Analysis of spleens from CD40L-DC-treated animals demonstrated that CD40L-DCs injected into the subcutaneous CT26 flank tumors migrated to the spleen, resulting in activation of immune-relevant processes. Consistent with this concept, intratumoral administration of CD40L-DCs elicited tumor-specific cytotoxic T-lymphocyte responses, and the transfer of spleen cells from CD40L-DC-treated mice efficiently protected naive mice against a subsequent tumor challenge. In a distant 2-tumor model of metastatic disease, an untreated B16 tumor in the right flank regressed in parallel with a left B16 tumor treated with direct injection of CD40L-DCs. These results support the concept that genetic modification of DCs with a recombinant CD40L adenovirus vector may be a useful strategy for directly activating DCs for cancer immunotherapy. (C) 2000 by The American Society of Hematology.

AB - CD40 ligand (CD40L) is essential for the initiation of antigen-specific T-cell responses. This study is based on the hypothesis that dendritic cells (DCs) genetically modified ex vivo to express CD40L will enhance in vivo presentation of tumor antigen to the cellular immune system with consequent induction of antitumor immunity to suppress tumor growth. To examine this concept, subcutaneous murine tumors were injected with bone marrow-derived DCs that had been modified in vitro with an adenovirus (Ad) vector expressing murine CD40L (AdmCD40L). In B16 (H-2 b, melanoma) and CT26 (H-2(d), colon cancer murine models, intratumoral injection of 2 x 10 6 Adm-CD40L-modified DCs (CD40L-DCs) to established (day 8) subcutaneous tumors resulted in sustained tumor regression and survival advantage. This antitumor effect was sustained when the number of CD40L-DCs were reduced 10-fold to 2 x 10 5. Analysis of spleens from CD40L-DC-treated animals demonstrated that CD40L-DCs injected into the subcutaneous CT26 flank tumors migrated to the spleen, resulting in activation of immune-relevant processes. Consistent with this concept, intratumoral administration of CD40L-DCs elicited tumor-specific cytotoxic T-lymphocyte responses, and the transfer of spleen cells from CD40L-DC-treated mice efficiently protected naive mice against a subsequent tumor challenge. In a distant 2-tumor model of metastatic disease, an untreated B16 tumor in the right flank regressed in parallel with a left B16 tumor treated with direct injection of CD40L-DCs. These results support the concept that genetic modification of DCs with a recombinant CD40L adenovirus vector may be a useful strategy for directly activating DCs for cancer immunotherapy. (C) 2000 by The American Society of Hematology.

UR - http://www.scopus.com/inward/record.url?scp=0034234661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034234661&partnerID=8YFLogxK

M3 - Article

C2 - 10891436

AN - SCOPUS:0034234661

VL - 96

SP - 91

EP - 99

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -